Oxfordshire, United Kingdom

Petra Dietrich

This inventor holds 1 USPTO granted patent. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Petra Dietrich: Innovator in Bicyclic Compound Synthesis

Introduction: Petra Dietrich is a notable inventor based in Oxfordshire, GB, renowned for her groundbreaking work in the field of organic chemistry. Her innovative contributions have paved the way for advancements in the synthesis of important pharmaceutical compounds.

Latest Patents: Petra holds a patent for a process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof, which is especially useful as an intermediate in the manufacture of a caspase inhibitor. This invention details a process for simultaneously N(2)-acylating piperazic acid or its esters while forming a bicyclic ring structure. Furthermore, it highlights the application of this process in synthesizing bicyclic compounds that serve as intermediates for producing an inhibitor of interleukin-1β converting enzyme (ICE).

Career Highlights: Petra currently works at Vertex Pharmaceuticals, Inc., where she continues to innovate in drug development. Her work has significantly contributed to the field of pharmaceuticals, particularly in creating inhibitors crucial for managing various diseases.

Collaborations: Throughout her career, Petra has collaborated with esteemed colleagues such as Andrea L C Robidoux and Jeffrey Douglas Wilson, working synergistically to enhance their shared goals in drug discovery and development.

Conclusion: Petra Dietrich exemplifies the spirit of innovation through her focused research and patent that addresses critical needs in pharmaceutical manufacturing. Her contributions not only advance scientific knowledge but also have the potential to impact therapeutic treatments significantly.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…